At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories. That it depends thereby less on large names, but on the future potential and whether the market also recognizes these perspectives, was one of its first learnings at the stock exchange.
On these pages, Nico examines current events at listed companies and takes a closer look at companies that are traded under the radar of the market, in addition to well-known securities.
In order to be able to take advantage of speculative opportunities on the stock exchange, Nico not only focuses on a balanced asset allocation of defensive and opportunity-oriented securities, but also on an intact risk management. "In addition to position size and entry in several tranches, investors should also develop a sense of timing and get to know a stock better before investing," says the columnist.
Commented by Nico Popp
Commented by Nico Popp on February 7th, 2022 | 13:22 CET
Meta, Desert Gold, Amazon: Of good and bad growth
Growth companies are out - at least, that is what many stock market commentators are saying these days. But can one of the most important drivers of high returns on the stock market ever lose its appeal? We explain what is meant by the saying around growth companies and show where there are still growth opportunities today.
Read
Commented by Nico Popp on February 4th, 2022 | 13:09 CET
Varta, Triumph Gold, Barrick Gold: Interest rate turnaround? That's what Goldman Sachs says!
Interest rates are rising - at least in the US, at least a little bit. But the market has turned signals of normalcy into warning signals. Rising interest rates could stall the recovery, and in general, rising rates would be poison for the stock market, which would become less attractive relative to interest-bearing securities. Here is why this argument is flawed, what Goldman Sachs has to say about it, and which stocks might benefit.
Read
Commented by Nico Popp on February 3rd, 2022 | 12:30 CET
NEL, Tembo Gold, Newmont: Comeback shares or save yourself?
The stock market is currently proving capricious: what was hot yesterday is already out again today. But there are good reasons to see opportunities in fallen angels. We take a closer look at some stocks that are not doing so well at the moment and analyze their comeback potential.
Read
Commented by Nico Popp on February 2nd, 2022 | 10:21 CET
Meta, Prospect Ridge, eBay: Opportunities beyond quarterly figures
Those who want to invest promisingly have a wide range of opportunities. Future technology offers itself. Ever since Facebook's parent company Meta announced its intention to create a digital ecosystem in which people can operate as if in a kind of parallel universe, there has been a gold-rush atmosphere around the "Metaverse". We take a look at the "Metaverse" from the perspective of other promising industries.
Read
Commented by Nico Popp on February 1st, 2022 | 10:38 CET
BYD, BrainChip, Daimler: The chip strategy decides
As Handelsblatt recently wrote, the automotive industry is still suffering from a chip shortage. As the leading media reports, according to the European Union, around 11.3 million new cars could not roll off the production line due to supply difficulties. Europe now wants to counter this with its own chip strategy. We highlight three stocks and explain who can profit.
Read
Commented by Nico Popp on January 31st, 2022 | 11:56 CET
MedTech with billion-dollar potential: Siemens Healthineers, Perimeter Medical Imaging, Sartorius
When we think of medical technology, we often think of the big players like Siemens Healthineers or the Fresenius Group. But the MedTech sector is characterized mainly by small and medium-sized companies. This is shown by a survey conducted by the German Medical Technology Association (BVMed). The experts have seen rising sales for years in this very diverse sector. Reason enough to shed light on a promising market from an investor's perspective. We present three companies and their shares.
Read
Commented by Nico Popp on January 27th, 2022 | 10:13 CET
Valneva, XPhyto, Peloton Interactive: What is next for pandemic stocks?
The pandemic is entering a new phase. Although incidences are rising towards the 1,000 mark, the population is largely relaxing. In the meantime, almost everyone knows someone who has fallen ill; as a rule, the scare is over quickly for those who have been vaccinated. In this article, we look at what this means for the stock market.
Read
Commented by Nico Popp on January 27th, 2022 | 06:00 CET
Interview Altech Advanced Materials: "We make batteries in e-cars more powerful and more durable".
Uwe Ahrens, director of Altech Advanced Materials, is convinced that e-cars will soon be cheaper than combustion engines. Ahrens and his team are pushing ahead with innovations and are not afraid of a price war in the battery industry. The reason: with its technology, the Company sees the potential to make batteries for e-cars significantly more powerful. Find out how this works and what other aces Altech Advanced Materials has up its sleeve in an interview with the experienced industry manager.
Read
Commented by Nico Popp on January 26th, 2022 | 11:01 CET
Bayer, MAS Gold, BASF: 5.7% dividend? These intrinsic values score now!
According to capital market strategist Ulrich Stephan from Deutsche Bank, substantial stocks could have an advantage in the upcoming market phase. The reason: When interest rates rise, the refinancing costs for growth companies increase significantly, as they usually do not write any or few profits. Reason enough to take a closer look at two of the best-known German substance companies and ask whether there are also growth stocks with substance.
Read
Commented by Nico Popp on January 25th, 2022 | 10:15 CET
BioNTech, Defence Therapeutics, Nordex: Investors must pay attention here!
"Defying cancer" was the headline of the Frankfurter Allgemeine Zeitung a few days ago. The interview was illustrated with the two leading BioNTech heads, Özlem Türeci and Uğur Şahin. The famous German scientists' statement revolved around further projects for BioNTech and the fight against cancer. At the same time, BioNTech's stock, like many other pandemic winners, dropped. What does this mean for investors now?
Read